PALISADE BIO, INC. (PALI) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 5.25M USD | Liabilities, Current |
| Cash and equivalents | 125.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 500.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.25M | $125.17M | (m) | $500.00K | (m) | (m) |
| 2026-03-31 | (m) | $5.62M | $132.63M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.64M | $133.38M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.48M | $5.23M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $3.97M | $5.42M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.78M | $7.23M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $3.24M | $9.82M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.68M | $8.04M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $2.84M | $11.35M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.47M | $11.28M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.59M | $12.43M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.65M | $15.31M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.33M | $16.40M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.31M | $13.30M | (m) | $250.00K | (m) | (m) |
| 2022-12-31 | (m) | $3.01M | $12.38M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $3.51M | $13.98M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.86M | $4.98M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.86M | $6.64M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.50M | $10.49M | (m) | $0.00 | (m) | (m) |
| 2021-09-30 | (m) | $2.92M | $14.10M | (m) | $0.00 | (m) | (m) |
| 2021-06-30 | (m) | $3.85M | $12.65M | (m) | $59.00K | (m) | (m) |
| 2021-03-31 | (m) | $1.01M | $6.56M | (m) | $25.26K | (m) | (m) |
| 2020-12-31 | (m) | $3.21M | $10.53M | (m) | $116.28K | (m) | (m) |
| 2020-09-30 | (m) | $1.00M | $12.65M | (m) | $8.78K | (m) | (m) |
| 2020-06-30 | (m) | $675.98K | $15.83M | (m) | $16.94K | (m) | (m) |
| 2020-03-31 | (m) | $1.19M | $10.03M | (m) | $19.01K | (m) | (m) |
| 2019-12-31 | (m) | $1.22M | $5.11M | (m) | $21.06K | (m) | (m) |
| 2019-09-30 | (m) | $1.58M | $7.30M | (m) | $61.15K | (m) | (m) |
| 2019-06-30 | (m) | $1.07M | $2.28M | (m) | $169.91K | (m) | (m) |
| 2019-03-31 | (m) | $1.21M | $4.01M | (m) | $237.78K | (m) | (m) |
| 2018-12-31 | (m) | $1.05M | $5.79M | (m) | $294.06K | (m) | (m) |
| 2018-09-30 | (m) | $1.18M | $5.74M | (m) | $161.98K | (m) | (m) |
| 2018-06-30 | (m) | $766.00K | $7.09M | (m) | $478.72K | (m) | (m) |
| 2018-03-31 | (m) | $1.28M | $9.72M | (m) | $137.37K | (m) | (m) |
| 2017-12-31 | (m) | $1.51M | $6.67M | (m) | $312.80K | (m) | (m) |
| 2017-09-30 | (m) | $1.83M | $9.06M | (m) | $37.46K | (m) | (m) |
| 2017-06-30 | (m) | $2.30M | $6.44M | (m) | $5.34K | (m) | (m) |
| 2017-03-31 | (m) | $5.05M | $11.68M | (m) | $14.71K | (m) | (m) |
| 2016-12-31 | (m) | $7.33M | $15.19M | (m) | $10.49K | (m) | (m) |
| 2016-09-30 | (m) | $7.85M | $5.68M | (m) | $12.69K | (m) | (m) |
| 2016-06-30 | (m) | $8.61M | $11.13M | (m) | $5.08K | (m) | (m) |
| 2016-03-31 | (m) | $7.62M | $7.62M | (m) | $39.17K | (m) | (m) |
| 2015-12-31 | (m) | $6.52M | $4.72M | (m) | $37.32K | (m) | (m) |
| 2015-09-30 | (m) | $7.47M | $13.13M | (m) | $19.16K | (m) | (m) |
| 2015-06-30 | (m) | $5.91M | $8.65M | (m) | $18.82K | (m) | (m) |
| 2015-03-31 | (m) | $4.34M | $13.59M | (m) | $8.17K | (m) | (m) |
| 2014-12-31 | (m) | $4.01M | $12.52M | (m) | $225.52K | (m) | (m) |
| 2014-09-30 | (m) | $5.70M | $11.95M | (m) | $32.76K | (m) | (m) |
| 2014-06-30 | (m) | $4.99M | $15.23M | (m) | $24.47K | (m) | (m) |
| 2014-03-31 | (m) | $4.67M | $18.34M | (m) | $11.36K | (m) | (m) |
| 2013-12-31 | (m) | $5.94M | $16.85M | (m) | $10.00K | (m) | (m) |
| 2013-09-30 | (m) | $5.15M | $16.40M | (m) | $7.50K | (m) | (m) |
| 2013-06-30 | (m) | $3.01M | $11.17M | (m) | $56.76K | (m) | (m) |
| 2013-03-31 | (m) | $2.65M | $12.66M | (m) | $104.25K | (m) | (m) |
| 2012-12-31 | (m) | $1.76M | $7.44M | (m) | $3.33K | (m) | (m) |
| 2012-09-30 | (m) | $2.12M | $9.87M | (m) | $833.00 | (m) | (m) |
| 2012-06-30 | (m) | $1.47M | $2.54M | (m) | $56.93K | (m) | (m) |
| 2012-03-31 | (m) | $2.31M | $5.14M | (m) | $234.38K | (m) | (m) |
| 2011-12-31 | (m) | $2.43M | $2.35M | (m) | $234.38K | (m) | (m) |
| 2011-09-30 | (m) | $1.99M | $4.20M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.15M | $6.14M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $8.55M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $2.74M | $9.26M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $11.59M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $14.03M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $2.31M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $4.90M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |